MedTrace Logo

Study Comparing Imatinib With Chemotherapy as Induction in Elderly Patients With Philadelphia Positive Acute Lymphoblastic Leukemia (ALL)

NCT00199186 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2007-10-19

No results posted yet for this study

Summary

The aims of the study are to determine whether single agent imatinib (STI571; Glivec) is more effective as up-front remission induction therapy than conventional multi-agent induction chemotherapy for elderly patients with Philadelphia positive (Ph+)ALL, whether this treatment is better tolerated, and whether subsequent combination therapy with imatinib and chemotherapy of approximately a 1 year duration is tolerable and effective with respect to maintaining remissions.

Conditions

  • Philadelphia Positive Acute Lymphoblastic Leukemia
  • Lymphoid Blastic Phase of Chronic Myeloid Leukemia

Interventions

DRUG

imatinib

DRUG

vincristine

DRUG

cyclophosphamide

DRUG

cytosine arabinoside

DRUG

dexamethasone

DRUG

idarubicin

DRUG

methotrexate (intrathecal)

DRUG

AraC (intrathecal)

DRUG

dexamethasone (intrathecal)

Sponsors & Collaborators

  • Johann Wolfgang Goethe University Hospital

    lead OTHER

Principal Investigators

  • Oliver G Ottmann, M.D. · Medizinische Klinik II, Johann Wolfgang Goethe Universität

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
56 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-03-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00199186 on ClinicalTrials.gov